On 3/17/2019, Boston Scientific announced positive results from the AF-FICIENT I study that evaluated the safety and efficacy of its LUMINIZE™ Radiofrequency (RF) Balloon Catheter. This recently acquired single-shot ablation technology is designed to isolate the pulmonary veins (PV) when treating patients with atrial fibrillation (AF). The device identifies the areas of the heart muscle that are responsible for abnormal heart rhythms using RF energy. Meanwhile, Boston Scientific continues to innovate in the space of cardiac health, including a patent application assigned to one of its subsidiaries, Cardiac Pacemakers, that details directly measuring heart sounds using mobile device accelerometers.